gemcitabine,interferon alfa-2b,docetaxel,pembrolizumab,Vibostolimab,Favezelimab
biogen,merck
['docetaxel', 'mibc', 'pembro', ' cis ', 'nmibc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'interferon alfa-2b', 'gemcitabine', 'bladder']
expanding landscape of bcg unresponsive non-muscle invasive #bladdercancer by #gu23: pembrolizumab (fda approved) adstilladrin (very recently fda approved) gemcitabine/docetaxel (based on prospective data) bcg with n803 (a mutant il-15 superantagonist) 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast